Keywords: Cornerstone Thera, Bethkis, US rights, Cystic fibrosis, Chiesi Farma
Cornerstone Thera gets US rights to Chiesi's Bethkis
Article | 11 November 2012
USA-based specialty pharma firm Cornerstone Therapeutics Inc. (Nasdaq: CRTX) says it has entered into an agreement with privately-owned Italian drugmaker ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
